AGLE Aeglea BioTherapeutics Inc.

7.39
-0.25  -3%
Previous Close 7.64
Open 7.68
Price To Book 2.69
Market Cap 214,202,978
Shares 28,985,518
Volume 48,945
Short Ratio
Av. Daily Volume 59,356
Stock charts supplied by TradingView

NewsSee all news

  1. Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

    AUSTIN, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with

  2. Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

    AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with

  3. Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences

    AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with

  4. Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights

    AUSTIN, Texas, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with

  5. Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer

    AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102
Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)
Phase 3 trial initiation announced June 3, 2019 with data due 1Q 2021.
Pegzilarginase (AEB1102)
Arginase I deficiency
Phase 1 dose escalation data presented at AACR April 15, 2018.
AEB1102
Solid tumors
Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102)
Solid tumors
Phase 1/2 trial ongoing.
Pegzilarginase (AEB1102) + KEYTRUDA
Small cell lung cancer (SCLC)
Phase 1/2 trial to be initiated 2Q 2020 with initial data due 1Q 2021.
AEB4104
Homocystinuria

Latest News

  1. Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

    AUSTIN, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with

  2. Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

    AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with

  3. Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences

    AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with

  4. Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights

    AUSTIN, Texas, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with

  5. Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer

    AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with

  6. Aeglea BioTherapeutics to Present at 21st Annual H.C. Wainwright Global Investment Conference

    AUSTIN, Texas, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with

  7. Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium

    Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79% Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 AUSTIN, Texas, Sept. 03, 2019

  8. Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium

    Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79% Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 AUSTIN, Texas, Sept. 03, 2019

  9. Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium

    AUSTIN, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with